AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for AMAG
46.12
-0.64 (-1.37%)
Jan 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 44.51 - 46.68
52 week 16.49 - 48.50
Open 46.26
Vol / Avg. 647,773.00/584,244.00
Mkt cap 1.04B
P/E     -
Div/yield     -
EPS -0.50
Shares 22.09M
Beta 0.03
Inst. own 122%
Feb 4, 2015
Q4 2014 AMAG Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 14, 2015
AMAG Pharmaceuticals Inc at JPMorgan Healthcare Conference
Nov 20, 2014
AMAG Pharmaceuticals Inc at Jefferies Global Healthcare Conference - London - Webcast
Oct 30, 2014
Q3 2014 AMAG Pharmaceuticals Inc Earnings Release
Oct 30, 2014
Q3 2014 AMAG Pharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 5.72% -11.88%
Operating margin 16.84% -14.37%
EBITD margin - -9.22%
Return on average assets 1.30% -3.67%
Return on average equity 3.00% -5.56%
Employees 148 -
CDP Score - -

Address

1100 Winter Street
WALTHAM, MA 02451
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company markets Feraheme (ferumoxytol) and MuGard Mucoadhesive Oral Wound Rinse. Feraheme Injection for Intravenous (IV) is indicated for the treatment of iron deficiency anemia in adult patients with CKD. The Company offers Feraheme to both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD. MuGard is indicated for the management of oral mucositis/stomatitis and all types of oral wounds (mouth sores and injuries). Lumara Health, Inc. (Lumara Health), a division of AMAG Pharmaceuticals, is dedicated to advancing women�s health. Lumara Health is the exclusive marketer of Makena (hydroxyprogesterone caproate injection), a FDA-approved product indicated to reduce the risk of pre-term birth in women who are pregnant with one baby and who have delivered one pre-term baby spontaneously in the past.

Officers and directors

Gino Santini Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
William K. Heiden President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frank E. Thomas Chief Operating Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 39
Bio & Compensation  - Reuters
Scott B. Townsend Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President, Chief Development and Regulatory Officer
Age: 54
Bio & Compensation  - Reuters
Melissa Bradford Klug Senior Vice President - Business Development and Strategy
Bio & Compensation  - Reuters
Robert Blood Esq. Chief Compliance Officer, Vice President - Legal Affairs
Bio & Compensation  - Reuters
Judith Johnson M.D. Vice President - Pharmacovigilance & Pharmacoepidemiology
Bio & Compensation  - Reuters